CCM
CARM

Consonance Capital Management’s Carisma Therapeutics CARM Stock Holding History

Consonance Capital Management’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-376,165
Closed -$10.7M – 27
2018
Q4 		$10.7M Hold
376,165
– – 0.79% 21
2018
Q3 		$16.2M Hold
376,165
– – 0.87% 27
2018
Q2 		$14.7M Buy
+376,165
New +$16.6M 0.95% 25

Other funds holding CARM

KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $855M AUM 14.24% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Consonance Capital Management's CARM Position: Q1 2019 in Review

Consonance Capital Management sold out of Carisma Therapeutics (CARM) in Q1 2019, closing a stake of 376,165 shares — an estimated $10.7M sold.

Consonance Capital Management first reported a position in CARM in Q2 2018 and held it in 3 quarters. The position peaked at $16.2M in Q3 2018. 48 funds tracked by Wall St. Rank hold CARM as of Q1 2019.

  • Consonance Capital Management reported no remaining Carisma Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Consonance Capital Management sold 376,165 Carisma Therapeutics shares in Q1 2019, an estimated $10.7M.
  • Consonance Capital Management first reported a position in Carisma Therapeutics in Q2 2018 and held it in 3 quarters.
  • Consonance Capital Management's Carisma Therapeutics position peaked at $16.2M in Q3 2018.
  • 48 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2019.

Based on Consonance Capital Management's 13F filing for Q1 2019, filed 15 May 2019.